Ron Balm

Prof. Dr. Ron Balm

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
SBS.C. van Beek
S.C. van Beek
ACA.P. Conijn
A.P. Conijn
MKM.J. Koelemay
M.J. Koelemay
RBRon Balm
Ron Balm
There is clinical equipoise between open (OR) and endovascular aneurysm repair (EVAR) for the best treatment of ruptured abdominal aortic aneurysm (RAAA). The aim of the study was to perform a systematic review and meta-analysis to estimate the short-term (combined 30-day or in-hospital) survival after EVAR and OR for patients with RAAA. Data sources included Medline, Embase, and the World Health Organization International Clinical Trials Registry until 13 January 2014. All randomised controlled trials (RCTs), observational cohort studies, and administrative registries comparing OR and EVAR of at least 50 patients were included. Articles were full-length and in English. Standard PRISMA guidelines were followed. The methodological quality of RCTs was assessed with the Cochrane Collaboration's tool for assessing risk of bias. The quality of observational studies was assessed with a modified Cochrane Collaboration's tool for assessing risk of bias, the Newcastle-Ottawa Scale, and the Methodological Index for Non-Randomized Studies. The results of the RCTs, of the obersvational studies, and of the administrative registries were pooled separately and analysed with the use of a random effects model. From a total of 3,769 articles, three RCTs, 21 observational studies, and eight administrative registries met the inclusion criteria. In the RCTs, the risk of bias was lowest and the pooled odds ratio for death after EVAR versus OR was 0.90 (95% CI 0.65-1.24). The majority of the observational studies had a high risk of bias and the pooled odds ratio for death was 0.44 (95% CI 0.37-0.53). The majority of the administrative registries had a high risk of bias and the pooled odds ratio for death was 0.54 (95% CI 0.47-0.62). Endovascular aneurysm repair is not inferior to open repair in patients with a ruptured abdominal aortic aneurysm. This supports the use of EVAR in suitable patients and OR as a reasonable alternative.

15 June 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MAMitzi van Andel
Mitzi van Andel
RIReza Indrakusuma
Reza Indrakusuma
HJHamid Jalalzadeh
Hamid Jalalzadeh
RBRon Balm
Ron Balm
JTJanneke Timmermans
Janneke Timmermans
MGMaarten Groenink
Maarten Groenink
The COMPARE trial showed a small but significant beneficial effect of 3-year losartan treatment on aortic root dilatation rate in adults with Marfan syndrome (MFS). However, no significant effect was found on clinical endpoints, possibly due to a short follow-up period. The aim of the current study was therefore to investigate the long-term clinical outcomes after losartan treatment. In the original COMPARE study (inclusion 2008–2009), adult patients with MFS (n = 233) were randomly allocated to either the angiotensin-II receptor blocker losartan® on top of regular treatment (β-blockers in 71% of the patients) or no additional medication. After the COMPARE trial period of 3 years, study subjects chose to continue their losartan medication or not. In a median follow-up period of 8 years, 75 patients continued losartan medication, whereas 78 patients, originally allocated to the control group, never used losartan after inclusion. No differences existed between baseline characteristics of the two groups except for age at inclusion [losartan 34 (interquartile range, IQR 26–43) years, control 41 (IQR 30–52) years; P = 0.031], and β-blocker use (losartan 81%, control 64%; P = 0.022). A pathological FBN1 mutation was present in 76% of patients and 58% of the patients were male. Clinical endpoints, defined as all-cause mortality, aortic dissection/rupture, elective aortic root replacement, reoperation, and vascular graft implantation beyond the aortic root, were compared between the two groups. A per-patient composite endpoint was also analysed. Five deaths, 14 aortic dissections, 23 aortic root replacements, 3 reoperations, and 3 vascular graft implantations beyond the aortic root occurred during follow-up. Except for aortic root replacement, all endpoints occurred in patients with an operated aortic root. Patients who used losartan during the entire follow-up period showed a reduced number of events compared to the control group (death: 0 vs. 5, P = 0.014; aortic dissection: 3 vs. 11, P = 0.013; elective aortic root replacement: 10 vs. 13, P = 0.264; reoperation: 1 vs. 2, P = 0.463; vascular graft implantations beyond the aortic root 0 vs. 3, P = 0.071; and composite endpoint: 14 vs. 26, P = 0.019). These results remained similar when corrected for age and β-blocker use in a multivariate analysis. These results suggest a clinical benefit of combined losartan and β-blocker treatment in patients with MFS.

1 May 2021 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
SMSana Mulay
Sana Mulay
AGAnna C.M. Geraedts
Anna C.M. Geraedts
MKMark J.W. Koelemay
Mark J.W. Koelemay
RBRon Balm
Ron Balm
JEJ.W. Elshof
J.W. Elshof
CZC.J. Zeebregts
C.J. Zeebregts
The aims of the present study were to examine the impact of type 2 endoleaks (T2EL) on overall survival and to determine the need for secondary intervention after endovascular aneurysm repair (EVAR). A multicentre retrospective cohort study in the Netherlands was conducted among patients with an infrarenal abdominal aortic aneurysm (AAA) who underwent EVAR between 2007 and 2012. The primary endpoint was overall survival for patients with (T2EL+) or without (T2EL-) a T2EL. Secondary endpoints were sac growth, AAA rupture, and secondary intervention. Kaplan-Meier survival and multivariable Cox regression analysis were used. A total of 2 018 patients were included. The median follow up was 62.1 (range 0.1 - 146.2) months. No difference in overall survival was found between T2EL+ (n = 388) and T2EL- patients (n = 1630) (p = .54). The overall survival estimates at five and 10 years were 73.3%/69.4% and 45.9%/44.1% for T2EL+/T2EL- patients, respectively. Eighty-five of 388 (21.9%) T2EL+ patients underwent a secondary intervention. There was no difference in overall survival between T2EL+ patients who underwent a secondary intervention and those who were treated conservatively (p = .081). Sac growth was observed in 89 T2EL+ patients and 44/89 patients (49.4%) underwent a secondary intervention. In 41/44 cases (93.1%), sac growth was still observed after the intervention, but was left untreated. Aneurysm rupture occurred in 4/388 T2EL patients. In Cox regression analysis, higher age, ASA classification, and maximum iliac diameter were significantly associated with worse overall survival. No difference in overall survival was found between T2EL+ and T2EL- patients. Also, patients who underwent a secondary intervention did not have better survival compared with those who did not undergo a secondary intervention. This study reinforces the need for conservative treatment of an isolated T2EL and the importance of a prospective study to determine possible advantages of the intervention.

1 September 2016 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
HJH. Jalalzadeh
H. Jalalzadeh
RIR. Indrakusuma
R. Indrakusuma
RPR N Planken
R N Planken
DLD.A. Legemate
D.A. Legemate
MKM.J.W. Koelemay
M.J.W. Koelemay
RBRon Balm
Ron Balm

1 October 2016 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
RIR. Indrakusuma
R. Indrakusuma
HJH. Jalalzadeh
H. Jalalzadeh
RPR N Planken
R N Planken
Henk MarqueringHenk Marquering
Henk Marquering
DLD.A. Legemate
D.A. Legemate
RBRon Balm
Ron Balm

1 September 2014 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
AKA.M. Knops
A.M. Knops
AGA. Goossens
A. Goossens
DUDirk Ubbink
Dirk Ubbink
RBRon Balm
Ron Balm
MKM.J.W. Koelemay
M.J.W. Koelemay
DLD.A. Legemate
D.A. Legemate